Uric Acid and Circulatory Diseases: From Biomarker to Potential Cardiovascular Risk Factor
Global Journal of Medical and Clinical Case Reports · 27.10.2026 · 273-276
DOI: 10.17352/gjmccr.000274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Journal of Medical and Clinical Case Reports, online erschienen am 27.10.2026. Verfasst von Ennio Duranti und 1 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hyperuricemia has traditionally been regarded as a biochemical marker of gout and urate crystal deposition diseases. In recent years, increasing experimental and epidemiological evidence has suggested a broader role for serum uric acid (SUA) in the development and progression of cardiovascular and circulatory disorders.
Objective
To review the current evidence linking hyperuricemia with vascular disease and to discuss the potential pathophysiological mechanisms underlying its association with cardiovascular morbidity and mortality.
Methods
A narrative review of experimental, epidemiological, and clinical studies evaluating the relationship between serum uric acid and major circulatory diseases, including hypertension, coronary artery disease, heart failure, cerebrovascular disease, and peripheral arterial disease.
Results
Elevated SUA levels are associated with endothelial dysfunction, oxidative stress, chronic inflammation, vascular smooth muscle proliferation, and activation of the renin-angiotensin-aldosterone system. These mechanisms contribute to vascular remodeling and atherosclerosis. Numerous observational studies have demonstrated independent associations between hyperuricemia and arterial hypertension, coronary artery disease, heart failure, stroke, peripheral arterial disease, and cardiovascular mortality. Furthermore, hyperuricemia frequently coexists with chronic kidney disease, diabetes mellitus, obesity, and metabolic syndrome, supporting its role within the emerging cardio-renal-metabolic continuum.
Conclusions
Hyperuricemia is increasingly recognized as a potentially modifiable cardiovascular risk factor rather than merely a marker of comorbidity. Although definitive evidence of causality remains incomplete, current data support a significant contribution of uric acid to vascular damage and circulatory disease progression. Future randomized clinical trials are needed to establish whether urate-lowering therapies can improve cardiovascular outcomes beyond their established role in gout management.
Zitieren
APA
Duranti, E., & Duranti, D. (2026). Uric Acid and Circulatory Diseases: From Biomarker to Potential Cardiovascular Risk Factor. Global Journal of Medical and Clinical Case Reports, 273-276. https://doi.org/10.17352/gjmccr.000274
Vancouver
Duranti E, Duranti D. Uric Acid and Circulatory Diseases: From Biomarker to Potential Cardiovascular Risk Factor. Global Journal of Medical and Clinical Case Reports. 2026:273-276. doi:10.17352/gjmccr.000274
BibTeX
@article{Duranti2026,
author = {Duranti, Ennio and Duranti, Diletta},
title = {Uric Acid and Circulatory Diseases: From Biomarker to Potential Cardiovascular Risk Factor},
journal = {Global Journal of Medical and Clinical Case Reports},
year = {2026},
pages = {273--276},
doi = {10.17352/gjmccr.000274}
}
EUVIMED